The Relationship of Asthma Biologics to Remission for Asthma
Authors:
- 1 March 2021
- journal article
- review article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 9 (3) , 1090-1098
Abstract
No abstract availableKeywords
Funding Information
- Sanofi
- Boehringer Ingelheim
- GlaxoSmithKline
- Roche
- Novartis
- AstraZeneca
- Teva Pharmaceutical Industries
This publication has 24 references indexed in Scilit:
- Type 2 inflammation in asthma — present in most, absent in manyNature Reviews Immunology, 2014
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaNew England Journal of Medicine, 2014
- Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthmaJournal of Allergy and Clinical Immunology, 2014
- Remission and Persistence of Asthma Followed From 7 to 19 Years of AgePediatrics, 2013
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 2012
- Development and validation of the Composite Asthma Severity Index—an outcome measure for use in children and adolescentsJournal of Allergy and Clinical Immunology, 2012
- Safety and tolerability of omalizumabClinical & Experimental Allergy, 2009
- Development and cross-sectional validation of the Childhood Asthma Control TestJournal of Allergy and Clinical Immunology, 2007
- Long-Term Inhaled Corticosteroids in Preschool Children at High Risk for AsthmaNew England Journal of Medicine, 2006
- Development of the asthma control testJournal of Allergy and Clinical Immunology, 2004